PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is multicenter investigator-initiated randomized open-label phase II clinical trial to
compare prophylaxis of graft versus host disease treated with tacrolimus and mycophenolate
mofetil versus ruxolitinib after post-transplant cyclophosphamide.
In total 128 patients will be included in the study. After inclusion into the study and
performing of transplantation patients will be randomized in 1:1 proportion in two arms (64
patients per arm): arm A will include patients who will be treated with cyclophosphamide and
ruxolitinib for GVHD prophylaxis; arm B will include patients who will be treated with
cyclophosphamide, tacrolimus and MMF for GVHD prophylaxis. After the end of the treatment
patients will be followed-up during two years.